Recent Breakthrough in Sepsis Pathogen ID: Same-Day Results with T2Direct Diagnostics Enables Faster Targeted Therapy in Educational Webinar
YORBA LINDA, Calif. (PRWEB) June 06, 2018 -- Sepsis is one of the top challenges facing hospitals in terms of high mortality rates, poor clinical outcomes and high cost of care. One of the major hurdles to effective sepsis management is the limitations of conventional diagnostics, which rely on blood culture and take 1 to 5 or more days to identify sepsis-causing pathogens.
To advance sepsis care, hospitals are turning to T2MR®, a proven technology that does not rely on blood culture for results and has exquisite accuracy. This year, multiple new peer-reviewed studies have been published on the T2Candida® Panel and the recently FDA-cleared T2Bacteria® Panel, which provide sepsis pathogen ID results in 3 to 5 hours without the wait for blood culture, and potentially allowing for treatment on Day 0. Due to improved detection, these studies from the U.S. and EU demonstrate that clinicians are achieving faster-targeted therapy, better outcomes, enhanced stewardship, and reduced cost of care.
Dr. Cornelius J. Clancy, an associate professor of medicine at the University of Pittsburgh, will be the speaker for this event. Clancy received his doctorate of medicine from the University of Washington. Along with his associate professor role, he is the director of the Mycology Program at the university and is the chief of the Infectious Diseases Section at the VA Pittsburgh Health Care System.
LabRoots will host the webinar June 20, 2018, beginning at 7 a.m. PDT, 10 a.m. EDT. To learn more or to register, click here.
About T2 Biosystem
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida Panel, and T2Bacteria Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. For more information, please visit http://www.t2biosystems.com or contact us at info(at)t2biosystems(dot)com.
About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.
Karen Sorenson, LabRoots, Inc., http://www.LabRoots.com, +1 (619) 861-0590, [email protected]
Share this article